As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds. Prescriptions of this GLP-1 class of diabetes and weight-loss medications more than doubled between 2022 and 2023, a new tally finds. “In contrast, there was a 25.6% decrease in… read on > read on >







